
GeneDx Inc
Delivering personalized and actionable health insights that inform diagnosis, direct treatment, and improve drug discovery.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor | €0.0 Valuation: €0.0 2.6x EV/Revenue -1.6x EV/EBITDA | round | |
* | $75.0m | Debt | |
Total Funding | 000k |
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | (9 %) | 18 % | 11 % | (14 %) | 51 % | 34 % | 18 % |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | (127 %) | (200 %) | (169 %) | (63 %) | 4 % | - | - |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | (135 %) | (116 %) | (234 %) | (87 %) | (17 %) | - | - |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
R&D % of revenue | 41 % | 50 % | 37 % | 29 % | 15 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
GeneDx is a pioneering company in the field of clinical genomics and rare disease diagnostics. The company specializes in genetic testing, which involves analyzing a patient's DNA to identify changes or mutations that could be linked to various health conditions. GeneDx serves a diverse range of clients, including patients, families, and healthcare providers, who rely on its expertise to gain deeper insights into genetic disorders.
Operating in the healthcare and biotechnology market, GeneDx has established itself as a leader by sequencing more than 300,000 clinical patient exomes. An exome is the part of the genome that contains genes, which are crucial for understanding genetic diseases. The company uses advanced techniques to collect DNA samples from cheek swabs, blood, or other specimens. These samples are then sequenced to detect genetic variations. The results are analyzed by a team of technical and clinical experts, and a detailed report is sent back to the healthcare provider.
GeneDx's business model revolves around providing rapid and accurate genetic testing services. They offer products like GenomeXpress and XomeDx Xpress, which deliver results in as little as seven days. This quick turnaround is vital for critical cases where timely diagnosis can significantly impact treatment outcomes, reduce hospital stays, and lower healthcare costs.
The company generates revenue by charging for its genetic testing services. Healthcare providers, hospitals, and clinics pay for these tests to diagnose and manage genetic conditions in their patients. Additionally, GeneDx offers digital Patient Letters, which provide personalized genetic information to patients and their families, enhancing their understanding of the test results.
In summary, GeneDx is at the forefront of clinical genomics, offering rapid and reliable genetic testing services that cater to patients, families, and healthcare providers. Their innovative approach and deep clinical expertise make them a key player in the personalized medicine landscape.
Keywords: Clinical Genomics, Genetic Testing, Rare Diseases, DNA Sequencing, Healthcare Providers, Rapid Diagnosis, Personalized Medicine, Exome Sequencing, Genetic Variations, Patient Letters.
Tech stack
Investments by GeneDx Inc
Edit